From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Celadon Pharma is on a nutso valuation, it is dangerous but surely it is a short

By Tom Winnifrith | Saturday 13 May 2023


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Back on March 23 I did a bearcast on Celadon Pharma (CEL) HERE which initially saw the shares marked lower from 125p to c105p. But the company fought back with private briefings. It did not draw attention to my well founded misgivings by issuing an RNS “refuting” what I said. That was a smart move. Instead someone roped in the serial liar John Story to do a mass new media spam pushing the shares, the CEO also did a Proactive interview and, for a while it worked. The shares hit 180p. Ouch. But then they started slipping.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Ariana – Surprise!

Time left: 06:23:53